Lenvima Dosage

Generic name: lenvatinib
Drug classes: Multikinase inhibitors, VEGF/VEGFR inhibitors

Medically reviewed by  A Ras MD.

Recommended Adult Dosing

Dosage forms:  CAP: 4 mg, 10 mg; 4 mg convenience pack; 8 mg convenience pack; 10 mg convenience pack; 12 mg convenience pack; 14 mg convenience pack; 18 mg convenience pack; 20 mg convenience pack; 24 mg convenience pack

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments; D/C >1wk before elective surgery, restart >2wk after major surgery when wound fully healed

[4 mg convenience pack components]

Info: 5-day 4 mg daily dose pack contains lenvatinib 4 mg cap x5

[8 mg convenience pack components]

Info: 5-day 8 mg daily dose pack contains lenvatinib 4 mg cap x10

[10 mg convenience pack components]

Info: 5-day 10 mg daily dose pack contains lenvatinib 10 mg cap x5

[12 mg convenience pack components]

Info: 5-day 12 mg daily dose pack contains lenvatinib 4 mg cap x15

[14 mg convenience pack components]

Info: 5-day 14 mg daily dose pack contains lenvatinib 10 mg cap x5 and 4 mg cap x5

[18 mg convenience pack components]

Info: 5-day 18 mg daily dose pack contains lenvatinib 10 mg cap x5 and 4 mg cap x10

[20 mg convenience pack components]

Info: 5-day 20 mg daily dose pack contains lenvatinib 10 mg cap x10

[24 mg convenience pack components]

Info: 5-day 24 mg daily dose pack contains lenvatinib 10 mg cap x10 and 4 mg cap x5

Differentiated thyroid CA, locally recurrent or metastatic

[24 mg PO qd]

Info: for pts w/ progressive and radioactive iodine-refractory dz; do not open cap, but may dissolve cap in water or apple juice

Renal cell CA, advanced

[first-line tx, combo w/ pembrolizumab]

Dose: 20 mg PO qd w/ pembrolizumab for up to 2y, then may give as monotherapy; Info: do not open cap, but may dissolve cap in water or apple juice

[previously treated dz, combo w/ everolimus]

Dose: 18 mg PO qd; Info: for pts who have received prior antiangiogenic tx; do not open cap, but may dissolve cap in water or apple juice

Hepatocellular CA, unresectable

[first-line tx, <60 kg]

Dose: 8 mg PO qd; Info: dose based on ABW; do not open cap, but may dissolve cap in water or apple juice

[first-line tx, >60 kg]

Dose: 12 mg PO qd; Info: dose based on ABW; do not open cap, but may dissolve cap in water or apple juice

Endometrial carcinoma, advanced

[20 mg PO qd]

Info: for pts w/ non-microsatellite instability-high (MSI-H) or non-mismatch repair deficient (dMMR) progressive dz not eligible for curative surgery or XRT; use w/ pembrolizumab; do not open cap, but may dissolve cap in water or apple juice

Renal dosing

[differentiated thyroid CA, locally recurrent or metastatic]

CrCl 15-29: 14 mg qd; CrCl <15: not defined

HD/PD: not defined

[renal cell CA, advanced]

CrCl 15-29: 10 mg qd; CrCl <15: not defined

HD/PD: not defined

[hepatocellular CA, unresectable]

CrCl >30: no adjustment; CrCl <30: not defined

HD/PD: not defined

[endometrial carcinoma, advanced]

CrCl 15-29: 10 mg qd; CrCl <15: not defined

HD/PD: not defined

Hepatic dosing

[differentiated thyroid CA, locally recurrent or metastatic]

Child-Pugh Class C: 14 mg qd

[renal cell CA, advanced]

Child-Pugh Class C: 10 mg qd

[hepatocellular CA, unresectable]

Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: not defined

[endometrial carcinoma, advanced]

Child-Pugh Class C: 10 mg qd

SRC: NLM .